Market Overview

ARIAD , Foundation Medicine Announce Collaboration on AP26113 Study


Medicine and ARIAD
Pharmaceuticals (NASDAQ: ARIA) today announced a genomic
profiling collaboration to study AP26113, ARIAD's investigational
dual-inhibitor of ALK and EGFR in patients with non-small cell lung
cancer (NSCLC) and other cancers. Foundation Medicine will work with
ARIAD to generate genomic profile information for patients enrolled in
ARIAD's ongoing Phase 1/2 trial and these data will be matched with
clinical observations to understand the activity and selectivity profile
of AP26113.

“It is important that we have a deep molecular understanding of
patients' tumors as they begin treatment with AP26113, especially those
patients with complex prior treatment histories,” stated Timothy P.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ARIA)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Intesa Sanpaolo Q3 Net Profit Down 21%

UPDATE: Deutsche Bank Initiates Seadrill at Buy on Quality, Diversification